This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection . Oral presentationO123 To overdose or underdose? The question of Kaletra in children in the UK/Irish Collaborative HIV Paediatric Study (CHIPS)1 MRC Clinical Trials Unit, London, UK 2 Bristol Royal Hospital for Children, Bristol, UK 3 St Mary's Hospital, London, UK 4 Evelina Children's Hospital, London, UK 5 Our Lady's Hospital for Sick Children, Dublin, Ireland 6 Institute of Child Health, London, UK 7 Royal Liverpool Children's NHS Trust, Liverpool, UK 8 Great Ormond Street Hospital for Sick Children, London, UK
from Ninth International Congress on Drug Therapy in HIV Infection Journal of the International AIDS Society 2008, 11(Suppl 1):O8doi:10.1186/1758-2652-11-S1-O8
First paragraph (this article has no abstract)The licensed lopinavir/r paediatric total daily dose is 460 mg/m2 without, and 600 mg/m2 with concurrent NNRTIs. The 460 mg/m2 dose without NNRTIs was chosen in preference to 600 mg/m2 in a post-hoc drug-interaction analysis [1]. Excellent VL suppression was also reported (79% <400 c/ml at 48 wks) but was based on the higher 600 mg/m2 dose. Thus, some paediatricians prefer this higher dose regardless of concomitant NNRTI therapy. |




on Google Scholar







corresponding author email